Cargando…
Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation
In the Wuhan province of China, almost two years ago, in December 2019, the novel Coronavirus 2019 has caused a severe involvement of the lower respiratory tract leading to an acute life-threatening respiratory syndrome, coronavirus disease-19 (COVID-19). Subsequently, coronavirus 2 (SARS-CoV-2) rap...
Autores principales: | TUFAN, Abdurrahman, MATUCCI CERINIC, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Scientific and Technological Research Council of Turkey
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771052/ https://www.ncbi.nlm.nih.gov/pubmed/34844296 http://dx.doi.org/10.3906/sag-2110-179 |
Ejemplares similares
-
COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
por: TUFAN, Abdurrahman, et al.
Publicado: (2020) -
Old and new antirheumatic drugs for the treatment of COVID-19
por: Benucci, Maurizio, et al.
Publicado: (2020) -
Immunopathology of Hyperinflammation in COVID-19
por: Gustine, Joshua N., et al.
Publicado: (2021) -
Management of hyperinflammation in COVID-19 patients
por: Suberviola, Borja, et al.
Publicado: (2022) -
COVID-19 Hyperinflammation: What about Neutrophils?
por: Didangelos, Athanasios
Publicado: (2020)